View Older Stories View More Recent Stories

May 9, 2024 07:30AM Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
May 6, 2024 07:31AM Annovis Bio (ANVS) CEO Issues Letter to Shareholders
May 6, 2024 07:30AM Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Apr 29, 2024 10:11AM Annovis Bio (ANVS) Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Apr 29, 2024 10:10AM Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Apr 2, 2024 07:30AM Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
Apr 1, 2024 08:05AM Annovis Bio Inc. (ANVS) Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Apr 1, 2024 08:00AM Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Mar 20, 2024 07:30AM Annovis Bio Inc. (ANVS) Provides Data Announcement Update for Phase II/III Study of Buntanetap
Mar 20, 2024 07:30AM Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Feb 27, 2024 08:00AM Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
Feb 14, 2024 07:30AM Annovis Bio (ANVS) Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Feb 14, 2024 07:30AM Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Jan 30, 2024 08:00AM Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
Jan 24, 2024 08:00AM Annovis Bio Inc. (ANVS) Postpones Phase III Study Data Announcement
Jan 24, 2024 08:00AM Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
Dec 11, 2023 01:00PM Annovis Bio to Participate in the 139th Yale CEO Summit
Dec 5, 2023 07:33AM Annovis Bio Inc. (ANVS) Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Dec 5, 2023 07:30AM Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Dec 1, 2023 07:30AM Annovis Bio Appoints Andrew Walsh as Vice President Finance
Nov 27, 2023 07:30AM Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Oct 30, 2023 04:42PM Annovis Bio Inc. (ANVS) Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent DSMB
Oct 30, 2023 04:42PM Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
Oct 24, 2023 09:13AM Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
Oct 12, 2023 08:03AM Annovis Bio (ANVS) Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
Oct 12, 2023 08:02AM Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
Aug 15, 2023 07:20AM Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 18, 2023 08:18AM Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
Jun 27, 2023 07:32AM Annovis Bio Inc. (ANVS) Announces the Filing of a Groundbreaking Patent
Jun 27, 2023 07:30AM Annovis Bio Announces the Filing of a Groundbreaking Patent
Jun 20, 2023 12:05PM Annovis Bio Inc. (ANVS) Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients
Jun 20, 2023 12:05PM Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Bo
Jun 8, 2023 07:30AM Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
May 11, 2023 07:00AM Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
Apr 27, 2023 07:04AM Annovis Bio Inc. (ANVS) Issues US Patent Covering the Use of Lead Drug Candidate, Buntanetap
Apr 27, 2023 07:00AM Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
Apr 20, 2023 07:00AM ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
Apr 19, 2023 07:32AM Annovis Bio Inc. (ANVS) Reports Consistent Enrollment in Phase 2/3 Trial of buntanetap
Apr 19, 2023 07:30AM ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
Apr 13, 2023 07:30AM ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
Apr 11, 2023 09:04AM ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
Apr 3, 2023 07:30AM ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Feb 8, 2023 07:33AM Annovis Bio Inc. (ANVS) Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Feb 8, 2023 07:30AM Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Feb 1, 2023 07:30AM Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
Jan 25, 2023 07:31AM Annovis Bio Inc. (ANVS) Provides Update on Enrollment into Phase 3 Study of buntanetap
Jan 25, 2023 07:30AM ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
Jan 6, 2023 07:30AM Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
Nov 8, 2022 05:35PM Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update
Oct 20, 2022 07:30AM Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
View More Recent Stories View Older Stories